VANCOUVER, British Columbia, March 1, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it is adding a new RNAi therapeutic targeting ALDH2 for the treatment of alcohol dependence (AD) to its product pipeline.
